| Literature DB >> 32755620 |
Jin Kyeong Choi1, Charles E Egwuagu2.
Abstract
B lymphocytes play a central role in host immunity. They orchestrate humoral immune responses that modulate activities of other immune cells and produce neutralizing antibodies that confer lasting immunity to infectious diseases including smallpox, measles and poliomyelitis. In addition to these traditional functions is the recent recognition that B cells also play critical role in maintaining peripheral tolerance and suppressing the development or severity of autoimmune diseases. Their immune suppressive function is attributed to relatively rare populations of regulatory B cells (Bregs) that produce anti-inflammatory cytokines including interleukin 10 (IL-10), IL-35 and transforming growth factor-β. The IL-35-producing B cell (i35-Breg) is the newest Breg subset described. i35-Bregs suppress central nervous system autoimmune diseases by inducing infectious tolerance whereby conventional B cells acquire regulatory functions that suppress pathogenic Th17 responses. In this review, we discuss immunobiology of i35-Breg cell, i35-Breg therapies for autoimmune diseases and potential therapeutic strategies for depleting i35-Bregs that suppress immune responses against pathogens and tumor cells. Published by Elsevier Ltd.Entities:
Keywords: Breg immunotherapy; interleukin 10; interleukin 35; interleukin-35-producing Breg (i35-Breg); regulatory B cell (Breg)
Mesh:
Substances:
Year: 2020 PMID: 32755620 PMCID: PMC7779660 DOI: 10.1016/j.jmb.2020.07.019
Source DB: PubMed Journal: J Mol Biol ISSN: 0022-2836 Impact factor: 5.469